FDA panel backs new lymphoma drug

A Food and Drug Administration panel yesterday recommended the agency grant temporary approval to GlaxoSmithKline PLC's (GSK) proposed cancer drug to treat two rare types of leukemia and lymphoma in children and adults. GlaxoSmithKline is asking the FDA to approve the drug, known as Arranon, under the agency's so-called accelerated approval mechanism, which allows drugs to be granted approval based on less data than is normally required.

We'll see if the FDA accepts the panel's recommendation. Articles on the subject by Google

LymphomaInfo Social